Registration of amiloride in South Africa: Cutting the Gordian knot

B L Rayner,1 MB ChB, MMed (Internal Medicine), FCP (SA), PhD; J D Spence,2 MD, FRCPC (Neurology), FRCPC (Internal Medicine), FAHA; A Bryer,3 MB BCh, MMed (Neurology), FCP (SA), FCPsych (SA) PhD; M T Mpe,4 MB ChB, FCP (SA), MMed (Internal Medicine)

1 Division of Nephrology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
2 Neurology and Clinical Pharmacology, Western University, London, Canada
3 President, South African Stroke Society, and Division of Neurology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
4 President, Southern African Hypertension Society, South Africa

Corresponding author: B L Rayner (brian.rayner@uct.ac.za)

Amiloride is an antagonist of the renal tubular epithelial sodium channel (ENaC). As such, it is a diuretic that is both potassium and magnesium sparing. It is used for the treatment of potassium depletion and hypertension, and is the specific therapy for hypertension due to overactivity of the ENaC (Liddle syndrome and several additional genetic causes of the Liddle phenotype – low renin and low aldosterone). It is listed as a World Health Organization essential drug, but has never been registered in South Africa (SA) and can therefore only be prescribed under a Section 21 application to the SA Health Products Regulatory Authority (SAHPRA) on a case-by-case basis. In SA, >50% of patients treated for hypertension are not controlled. In the USA, the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study reported that African Americans are more likely to be diagnosed with hypertension, more likely to be treated, more likely to be treated intensively, and less likely to achieve blood pressure (BP) control. Although the reasons are complex, studies show that 10 - 20% of blacks may carry the Liddle phenotype. Observational data and a controlled clinical trial done in three African countries have shown that these patients respond to amiloride and not to conventional guideline-based antihypertensive treatment. The former is likely to result in a significant reduction in cardiovascular, stroke and kidney morbidity and mortality, because of improved BP control. Amiloride is very unlikely to ever be registered in SA, as it was first developed >50 years ago, and SAHPRA regulations prevent widespread prescription of this essential drug. This is a classic Gordian knot that requires a novel approach from authorities to sever the knot and improve the health of many South Africans.


Cutting the Gordian knot is a commonly used metaphor for solving an intractable problem that is resolved easily by a radically different approach. The legend dates to 333 BC when Alexander the Great marched into the city of Gordium in modern-day Turkey. On arriving, he encountered a wagon with its yoke tied in a knot, which no one could unfasten. After wrestling with the knot for some time, Alexander drew his sword and sliced the knot in half, so releasing the wagon from the yoke.

South Africa (SA) (and Africa) faces a similar problem in relation to the registration of amiloride for treatment of resistant or severe hypertension in the black African and mixed ancestry populations; there needs to be a radical new approach to address this pressing issue.

Amiloride is a potassium-sparing diuretic that blocks the epithelial sodium channel (ENaC) in the collecting duct of the kidney, resulting in natriuresis and retention of potassium and magnesium.[1] The ENaC is the final regulator of sodium balance in the kidney and therefore plays a crucial role in sodium regulation and blood pressure (BP) control.[2] The main indication for amiloride is for the treatment of hypertension; it is listed as a World Health Organization (WHO) essential drug.[3] Although developed >50 years ago, amiloride did not gain widespread use in the treatment of hypertension and is hardly mentioned in most hypertension guidelines.

Amiloride alone has never been registered in SA, but is available in a combination tablet with hydrochlorothiazide (HCTZ) (amiloride 5 mg, HCTZ 50 mg). Although this combination tablet may lower blood pressure, there are two problems: (i) the dose of HCTZ is too high, with a propensity for electrolyte abnormalities at full dose that can be severe and life threatening;[11] and (ii) if half the dose is used to minimise electrolyte abnormalities, the dose of amiloride (2.5 mg) is insufficient to adequately target the ENaC. As pure amiloride has never been registered, it can only be prescribed on a case-by-case basis, approved by the SA Health Products Regulatory Authority (SAHPRA) under a Section 21 application.

Targeting the ENaC is critically important in black Africans to control severe or resistant hypertension. Given the number of patients affected, this is not feasible when approval of the drug is required on a case-by-case basis. The reasons for targeting the ENaC in black hypertensive patients are a tale of two research groups working independently on two different continents, coming to the same conclusion, and then collaborating to perform a clinical trial that confirmed this approach.

The tale of amiloride
Cape Town, South Africa

The principal author (BLR) is a nephrologist and hypertension expert, who started working in the Hypertension Clinic at Groote
Schuur Hospital, Cape Town, SA, in 1994. He was struck by the number of patients with severe drug-resistant hypertension, despite good medication adherence. Based on the work of Richard Gordon from Brisbane, Australia, who found that the prevalence of primary aldosteronism (PA) in their locality was 12%, the aldosterone-renin ratio to screen patients with drug-resistant hypertension was implemented by him. Thirty-two percent of patients had evidence suggestive of primary aldosteronism, and the introduction of spironolactone made a dramatic difference to BP control in these patients.

Furthermore, during a screening programme to establish normal ranges of aldosterone and renin in three SA population groups (white, mixed ancestry and black), the mean plasma renin activity (PRA) and plasma aldosterone levels were significantly lower in black and mixed ancestry patients than in white patients, despite similar salt intake. Low PRA and plasma aldosterone levels are the hallmark of the Liddle syndrome, which is an inherited condition due to mutations in the beta chain of the ENaC. This results in excess expression of ENaC on the tubular cells of the collecting duct, resulting in increased sodium reabsorption despite suppressed aldosterone. The ENaC is a crucial site of salt balance and hence of BP control, as it is the final regulator of sodium balance in the kidney.

Consequently, the entire gene for the sodium channel epithelial beta (SCNN1B) subunit of the ENaC was sequenced and a novel single nucleotide polymorphism (SNP) (p.Arg563Gln or R563Q) was identified. It was later shown to be associated with low renin- and low aldosterone-related hypertension in indigenous southern African and Cape mixed ancestry population groups; there was a strong association with hypertension and the p.Arg563Gln mutation in blacks living in urban areas, and 5% of hypertensives were carriers. In a kindred study, the p.Arg563Gln mutation strongly associated with hypertension, and patients with severe hypertension carrying this mutation responded exceptionally well to amiloride, a specific inhibitor of ENaC. The prevalence of the p.Arg563Gln mutation was 20% in the Khoi-San population, who are hunter-gatherer people living in the Kalahari desert, suggesting that this was the population of origin (for this variant) and may have offered survival advantage in a sodium-restricted environment. In addition to true Liddle syndrome due to variants of ENaC, there are variants of at least 5 other genes that increase the activity of ENaC, resulting in a Liddle phenotype (GRK, NEDD4L, CYP4A11, NPPA, UMOD and perhaps others). Therefore, although the prevalence of true Liddle syndrome may be only ~6% among resistant hypertensives in Cape Town, the prevalence of a Liddle phenotype, also selectively responsive to amiloride, is apparently much higher, as discussed below.

**London, Canada**

The second author (JDS) is a neurologist and clinical pharmacologist in London, Ontario, Canada, with a special interest in hypertension and stroke prevention. He examined patients from an African American community in Buxton, near London, who were descendants of slaves who had escaped to Canada in the 1800s. Blacks were much more likely to have a low plasma renin, which at the time was attributed to primary aldosteronism, mostly due to bilateral adrenocortical hyperplasia (plasma aldosterone levels were then not available; therefore, the Liddle phenotype was unrecognised in that clinic population).

In 2006, Spence suggested that physiologically individualised therapy based on phenotyping with plasma renin and aldosterone had the potential to eliminate or at least markedly diminish the racial disparities in hypertension and stroke in the USA. A treatment algorithm was developed (Table 1), which resulted in excellent control rates for hypertension and a marked reduction in stroke.

**Physiologically individualised therapy in Africa**

A randomised clinical trial was implemented to test this hypothesis in Africa, and evidence supporting this approach is available in hypertension clinics in Nigeria, Kenya and SA. Patients whose BP was not controlled to <140 systolic mmHg or 90 diastolic mmHg were allocated to usual care (UC) v. physiologically individualised therapy (PhysRx).

In the overall study, control of both systolic and diastolic BP was obtained in 11.1% of UC-treated patients v. 50.0% of PhysRx-treated patients (p<0.0001). Systolic control was achieved in 13.9% of UC patients v. 60.3% of PhysRx patients (p<0.0001); and diastolic control was achieved in 36.1% of UC patients v. 67.2% of PhysRx patients (p=0.003). At the Nigerian site, where patients were randomised and conditions were more similar to those in North America, systolic control was obtained in 15% of UC patients v. 85% of PhysRx patients (p<0.0001); diastolic control in 45% of UC patients v. 75% of PhysRx patients (p=0.11); and control of both systolic and diastolic pressure in 15% of UC patients v. 75% of PhysRx patients (p<0.0001), even though the renal function was worse at that site. The major difference in medication change during the study was with amiloride; at the end of the study amiloride was being taken by 19% of PhysRx patients v. only 2.8% of UC patients (p=0.02). This indicates that 19% of these patients with resistant hypertension had a Liddle phenotype.

Furthermore, in this study, genetic analysis of candidate genes was undertaken in those with the Liddle phenotype. Most patients had variants of several different genes affecting ENaC function. Among those with a primary aldosteronism phenotype, all patients had variants of aldosterone synthase. In 2019, Spence hypothesised that...
some patients may have variants predisposing to both inappropriate aldosterone secretion and overactivity of the ENaC. For identification of physiologically appropriate therapy, it would be more practical to do phenotyping by measuring plasma renin and aldosterone than sequencing the beta chain of the ENaC and other genes that increase ENaC activity.

Case for amiloride in South Africa

In SA, hypertension is one of the leading causes of death, and 50% of treated hypertensive patients are not controlled.[16] In the USA, the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study showed that African Americans are more likely to be diagnosed with hypertension, more likely to be treated, more likely to be treated intensively, and less likely to achieve BP control.[17] Although the reasons are complex, including poor adherence and lack of access to antihypertensive medication, it is now apparent that a large proportion of uncontrolled hypertension in blacks is due to polymorphisms in genes that increase ENaC function, resulting in salt and water retention, with suppressed renin and aldosterone. Amiloride is the specific treatment for uncontrolled hypertension. This has been demonstrated in an uncontrolled study in SA and more importantly in the randomised trial of physiological individualised treatment of resistant hypertension, as discussed above.[18,19] Triamterene also blocks the ENaC and is available in SA in combination with HCTZ 25 mg. It causes renal casts in more than half of the patients – thought to be due to interstitial nephritis – and is not recommended.[19]

Given that it is estimated that >5% of black hypertensives in SA have proven mutations of the ENaC and 10 - 20% have resistant hypertension due to the Liddle phenotype, it is simply not feasible to seek individual approval for the number of patients affected. Requests to register amiloride by the company that originally developed it, have not been successful, presumably because there would be no patent protection. Generic companies also cannot import amiloride unless it has been registered by the company that produced the original brand. Amiloride is registered in SA in the combination tablet Amiloride Co (HCTZ 50 mg/amiloride 5 mg), and approaches to phenotyping by measuring plasma renin and aldosterone than sequencing the beta chain of the ENaC and other genes that increase ENaC activity.

Conclusions

Amiloride is a WHO essential drug that has been registered in SA, but only in a combination product with too high a dose of HCTZ. Use of amiloride in black and mixed ancestry patients with severe and resistant hypertension is highly likely to improve BP control, with resultant reduction in cardiovascular, stroke and kidney morbidity and mortality.

Declaration. None.

Acknowledgements. None.

Author contributions. BLR wrote the manuscript, which was critically reviewed by all the authors.

Funding. None.

Conflicts of interest. Dr JD Spence is a consultant to Amgen and Orphan Technologies, an officer of Vascularis Inc., and has received lecture fees from Pfizer and Bristol-Myers Squibb. Prof. B L Rayner has received lecture fees from Servier, Sanofi, Novartis, Cipla, Litha, AstraZeneca and Boehringer Ingelheim.

References


Accepted 3 June 2019.